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Abstract
Studies addressing the ontogeny of the innate immune system in early life have reported mainly on Toll-like receptor (TLR)
responses in infants living in high-income countries, with little or even no information on other pattern recognition
receptors or on early life innate immune responses in children living under very different environmental conditions in less-
developed parts of the world. In this study, we describe whole blood innate immune responses to both Toll-like and
nucleotide-binding oligomerization domain (NOD)-like receptor agonists including the widely used vaccine adjuvant ‘alum’
in a group of Papua New Guinean infants aged 1–3 (n = 18), 4–6 (n = 18), 7–12 (n = 21) and 13–18 (n = 10) months old.
Depending on the ligands and cytokines studied, different age-related patterns were found: alum-induced IL-1b and CXCL8
responses were found to significantly decline with increasing age; inflammatory (IL-6, IL-1b, IFN-c) responses to TLR2 and
TLR3 agonists increased; and IL-10 responses remained constant or increased during infancy, while TNF-a responses either
declined or remained the same. We report for the first time that whole blood innate immune responses to the vaccine
adjuvant alum decrease with age in infancy; a finding that may imply that the adjuvant effect of alum in pediatric vaccines
could be age-related. Our findings further suggest that patterns of innate immune development may vary between
geographically diverse populations, which in line with the ‘hygiene hypothesis’ particularly involves persistence of innate IL-
10 responses in populations experiencing higher infectious pressure.
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Introduction
The human immune system undergoes developmental changes
in postnatal life with some responses reaching adult-like profiles
at early age and others continuing to develop into late childhood.
This involves maturation of both the adaptive immune system
that is largely naı̈ve at birth and acquires memory to an
increasing variety of environmental exposures over time; and the
innate immune system, for which there is growing evidence that
functioning at birth is distinct from that of an adult. Several
studies have characterized innate immune responses to toll-like
receptor (TLR)-ligands in human neonates and adults; reporting
that the production of pro-inflammatory cytokines including
IFN-c, IL-12 and in some studies also TNF-a, is generally
impaired in neonates, while the production of IL-1b, IL-6, IL-10
and IL-23 is equal to or even higher than that produced by
adults [1–4]. This profile of innate cytokine response in
newborns favours T helper (Th) 2 rather than protective Th1
responses [5–7], which likely accounts for the high susceptibility
of newborns to infectious agents [1].
Most studies on the ontogeny of the human innate immune
system have been performed in high-income countries. Little is
known about whether these developmental patterns also apply to
children born in low-income countries where the burden of
infectious diseases is considerably higher, particularly in early life
[8,9]. One recent study reporting on TLR-mediated immune
responses in the first 12 months of life in infants in the Gambia,
Africa [10] found some patterns of immune maturation to be
different from what has been described for infants in the western
world [11–13]: instead of declining innate IL-10 and IL-6, and
gradually increasing TNF-a and IFN-c responses over the first
year of life, responses in Gambian infants remained stable between
1 and 12 month of age after TNF-a and IFN-c production had
increased during the first month of life. Moreover, there is some
evidence that environmental and lifestyle factors influence neo-
natal immune function (reviewed in [14,15]), as well as that infant
innate immune responses to Bacillus Calmette-Guérin (BCG)
vaccination varies between populations [16–18]. Altogether these
studies lend support to the hypothesis that innate immune
maturation is not uniform across populations of high-income
versus low-income settings.
There are currently no studies reporting on innate immune
responses to pattern recognition receptors (PRRs) other than
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TLRs in young infants [19]. Nucleotide-binding oligomerization
domain (NOD)-like receptors (NLRs) are PRRs that include both
NOD and NALP (NACHT-leucine rich repeat and pyrin-domain
containing proteins) receptors that detect microbial products and
endogenous danger signals [20–22]. NALPs form caspase-1-
activating multiprotein complexes (‘inflammasome’) which process
pro-inflammatory cytokines such as IL-1b and IL-18 to their
mature active form, and were described to mediate the immuno-
stimulatory properties of aluminium (‘alum’) adjuvants [23–25].
Interestingly, despite the fact that alum is widely used in pediatric
vaccines, there is currently no data available on alum-induced
responses in infancy.
Studying early immune development in low-income settings
may provide significant information on: (a) the pathways
responsible for the high susceptibility of newborns and infants
to infectious diseases; (b) responsiveness to vaccine adjuvants such
as alum and other candidate TLR and NLR agonists [26]; and
(c) the trajectory of early immune development and how this
relates to susceptibility to non-communicable inflammatory
diseases such as allergy in later life [27–30]. In this study, we
aimed to further explore the ontogeny of TLR and NLR-
mediated responses during infancy in a low-income country by
describing whole blood cytokine responses in Papua New
Guinean (PNG) infants aged 1–18 months old.
Methods
Ethics Statement
Written informed consent was obtained from all parents of
children participating in this study. Ethical approvals for this study
were obtained from the PNG Institute of Medical Research
Institutional Review Board (0714), the PNG Medical Research
Advisory Council (MRAC No 07/10 and No 09.18) and the
Ethics Committee of the Princess Margaret Hospital for Children,
Perth, Western Australia (1431/EP).
Study Design
This was a cross-sectional follow-up study of children partici-
pating in an earlier neonatal immunology study (n= 119),
performed between 2008 and 2009 in Goroka, PNG. In this area,
respiratory pathogens as well as intestinal helminthes and protozoa
are highly endemic: however, malaria is not prevalent due to its
location at high altitude (1500–1900 m above sea level). Infants
were followed-up in October-November 2009, when they were
between 1 and 18 months old. After parental consent was
obtained, follow-up visits to the PNG Institute of Medical
Research (IMR) clinic were arranged. A total of 83 children were
re-located. During this visit, infants were physically examined by
a study nurse, information on the child’s vaccination history,
medications and illnesses was collected, and a venous blood
sample was obtained where possible. Children were excluded from
the follow-up study if they had been diagnosed with a congenital
illness, were known to be HIV positive, had fever-related illness at
the time of follow-up, were no longer living in the study area or
where parents did not re-consent. Venous blood samples were
obtained from a total of 67 children (male n = 31, female n= 27,
data missing for 9 children) varying in age between 1 and 18
months old: aged 1–3 (n= 18), 4–6 (n= 18), 7–12 (n= 21) and 13–
18 (n= 10) months.
Children were vaccinated according the recommended national
immunization schedule, which changed during the period that this
birth cohort was born: whereas immunization with BCG and
Hepatitis B vaccine (HBV) remained recommended at birth,
a neonatal dose of oral polio vaccine was omitted from the later
schedule; and immunization with a pentavalent diphtheria,
tetanus, whole cell pertussis, Haemophilus influenzae type B and
hepatitis B combination vaccine (DTwP/HepB/Hib) at 1, 2, and 3
months replaced recommended immunization with separate
DTwP and Hib vaccines at 1, 2, and 3 months of age and HBV
at 1 and 3 months of age. Measles immunization remained
recommended at 6 and 9 months of age.
Whole Blood Cultures
Infant venous blood samples (2–5 ml) were collected into sterile
tubes containing 100 IU preservative-free heparin. Within 2 hrs
from collection, an aliquot of blood (500–750 ml) was diluted 5x in
RPMI and plated into 96-well round bottom plates (200 ml/well).
For ligands not used previously in any of our studies, cultures
were first optimized by comparing innate cytokine responses (IL-6,
IL-10, IFN-c and TNF-a) in cell cultures stimulated with three
increasing doses of the ligand during 6, 24 or 48 hours: 24 hours
was identified as the single time point giving the highest immune
responses for most ligand-cytokine combinations, and concentra-
tions inducing the overall best cytokine response were selected as
indicated for further experiments (data not shown).
To study the maturation of TLR immune responses, whole
blood cultures were stimulated with optimal doses of Staphylococcus
aureus-derived lipoteichoic acid (LTA, TLR2-ligand; 20 mg/mL;
InvivoGen, San Diego, USA), polyinosinic-polycytidylic acid
(PolyIC, TLR3-ligand; 50 mg/mL; Sigma, Saint Louis, USA),
Escherichia coli-derived lipopolysaccharide (LPS, TLR4-ligand;
1 ng/mL; Alexis Biochemicals, San Diego, USA) in the presence
or absence of recombinant human IFN-c (10 ng/mL; BD
Biosciences Pharmingen, San Diego, USA); or gardiquimod
(TLR7/8-ligand;10 mg/mL; InvivoGen, San Diego, USA).
Table 1. Infant characteristics.
Age group
1–3 months 4–6 months 7–12 months 13–18 months
Weight, kg (mean; SD) 6.1 (0.8) 7.2 (1.0) 8.7 (0.9) 9.6 (0.9)
Length, cm (mean; SD) 61.8 (3.3) 64.7 (3.5) 70.2 (4.2) 77.4 (4.0)
Body temperature, uC (mean; SD) 36.4 (0.3) 35.7 (2.4) 36.2 (0.8) 36.0 (0.7)
Still breastfed 16/17 (94%) 17/17 (100%) 13/15 (87%) 6/6 (100%)
Solid food introduced 9/17 (53%) 13/17 (76%) 15/15 (100%) 6/6 (100%)
Hospitalized at least once 3/15 (20%) 0/16 (0%) 3/14 (21%) 1/6 (17%)
doi:10.1371/journal.pone.0036793.t001
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To study maturation of NLR immune responses, blood samples
were stimulated with optimal doses of c-D-Glu-mDAP (iE-DAP,
NOD1-ligand; 5 mg/mL; InvivoGen, San Diego, USA) and
muramyl dipeptide (MDP, NOD2-ligand; 10 mg/mL; InvivoGen,
San Diego, USA. To observe age-dependent responses to NALP3
inflammasome activation, cells were stimulated with aluminium
potassium sulfate (Alum; 10 mg/mL, InvivoGen, San Diego, USA)
alone or in the presence of LPS (particularly for measurement of
mature IL-1b production as it is thought that the action of alum
requires an additional signal provided by TLR co-stimulation for
the initial synthesis of pro-IL-1b [23,24]).
Whole blood samples were also cultured without stimulation
(negative control for LTA, polyIC, LPS, gardiquimod, iE-DAP,
MDP and alum-stimulated cultures) or with IFN-c alone (negative
control for LPS + IFN-c-stimulated cultures) to correct for
background responses. For alum + LPS-stimulated cultures, the
LPS-stimulated response was subtracted as background.
Cultures were incubated at 37uC for 24 hours using the
Aerogen Compact Atmosphere Generation System (Oxoid)
according to previously published methods [31] to create a 5%
CO2 level, and supernatants harvested and stored at -80uC before
transferring to Perth via dry shipper for further experiments.
In Vitro Cord and Peripheral Blood Mononuclear Cell
(CBMC/PBMC) Cultures with Alum
CBMC had been isolated from cord blood of study children at
the time of enrolment at birth; and PBMC were isolated from
venous blood samples obtained from unrelated, healthy laboratory
volunteers in PNG (n=5). CBMC and PBMC were cryopre-
served, transferred via dry shipper and stored in Perth (as
previously described [32]) until use in functional assays. Thawed
cells (2.5x105/mL) were cultured in RPMI/10% NHI-FCS in 96-
well plates at 37uC/5% CO2 with or without alum (10 mg/mL) in
the presence or absence of LPS (1 ng/mL). Supernatants were
collected at 24 hours and stored at -20uC.
Cytokine and Chemokine Protein Detection
Cytokine levels were measured in supernatants using an in-
house multiplex assay as previously described [32].
For Alum experiments, levels of the chemokines IL-8 (CXCL8),
MCP-1 (MCAF), MIP-1a, MIP-1b, IP-10 and eotaxin in super-
natants were measured using a Bioplex Pro Chemokine Assay kit
(Human Group I: 6-plex panel, BIO-RAD, USA) according to the
manufacturer’s instructions.
All samples were read on a Bio-Plex Suspension Array System
(BIO-RAD, USA). Samples with concentrations below the de-
tection limit were given the value corresponding to half the lowest
concentration (3 pg/mL) that could be detected in this set of
samples. The proportion of PRR-stimulated samples with cytokine
concentrations below the detectable limit are shown in Table S1.
Samples with concentrations above the level of detection i.e.
30,000 pg/mL (generally only IL-6) were further diluted and re-
tested.
Statistical Methods
As log-transformed cytokine responses were not normally
distributed (assessed by QQ plots), differences in continuous
variables were tested for significance using the Mann Whitney U
test. To investigate the trajectory (slope) of the log-transformed
cytokine response with increasing age, non-parametric Spearman
rho correlations were performed and associated p-values used to
assess whether the slope was significantly different from zero.
Positive and negative coefficients suggest respective increases or
decreases in cytokine responses across ordered age levels.
Differences were considered to be statistically significant when
p-values were less than 0.05. All analyses were performed using
the statistical package SPSS 15.0.
Results
Infant Characteristics
Characteristics of the infant study population at the time of
follow-up are described in Table 1. All children were afebrile at
the time of assessment. Fifteen percent (7/46) of the children were
hospitalized at least once prior to follow-up, mainly for upper and
lower respiratory tract infections (data not shown).
Maturation of TLR and NLR Immune Responses
During Infancy
PNG infants aged 1–3, 4–6, 7–12 and 13–18 months old were
compared for immune responses to a range of innate stimuli
including TLR and NLR agonists (Figure 1).
A progressive and significant age-related increase in TLR2 and
TLR3-mediated inflammatory cytokine production, including IL-
6, IL-1b and IFN-c was observed (Figure 1 and Table 2). A similar
increase was observed for TLR3-induced IL-10 responses
(Table 3). TLR7/8-induced responses were found to be similar
across age groups (Figure 1 and Tables 2, 3, and 4). There were no
clear age-related changes in TNF-a production, except for
a significant decline in TLR4-induced levels between 1–3 and
7–12 months of age (Table 4). The innate production of IL-12
Figure 1. Maturation of innate immune function in PNG infants.Whole blood samples from PNG infants aged 1–3 months (n = 18, white bars),
4–6 months (n = 18, light grey bars), 7–12 months (n = 21, dark grey bars) or 13–18 months (n = 10, black bars) were stimulated with TLR (LTA; PolyIC;
LPS; Gardiquimod) and NLR (iE-DAP; MDP) ligands, and Alum alone or with LPS co-stimulation (denoted by¤). Presented are the geometric means
and 95% confidence intervals (pg/mL) for each age group for background-adjusted cytokine responses. Significance level is indicated where p,0.05.
doi:10.1371/journal.pone.0036793.g001









TLR2 0.271 0.027 0.237 0.054 0.248 0.043
TLR3 0.255 0.039 0.257 0.035 0.273 0.025
TLR4 0.122 0.325 0.135 0.277 0.161 0.192
TLR7/8 0.173 0.164 0.176 0.161 0.049 0.698
NOD1 0.088 0.477 20.118 0.340 0.082 0.507
NOD2 0.159 0.199 0.086 0.488 20.139 0.261
NALP3 20.099 0.429 20.151 0.225 20.071 0.572
NALP3¤ 20.014 0.913 20.368 0.002 20.158 0.201
Spearman rho correlation coefficients for the slope/trajectory of log-
transformed inflammatory cytokine responses across ordered age groups: 1–3,
4–6, 7–12 and 13–18 months were determined. Significance level is indicated;
bold-faced and italicized text highlight correlations with p,0.05.
¤denotes LPS co-stimulation used.
doi:10.1371/journal.pone.0036793.t002
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generally remained low and unchanged throughout infancy,
except in response to TLR3 stimulation and TLR4/IFN-c-primed
stimulation, whereby trends for increasing IL-12 with age were
observed (Figure 2).
With respect to NOD-associated pathways, infant responses
remained stable between 1 and 18 months of age (Figure 1,
Tables 2, 3, and 4). In contrast to TLR-induced IL-1b responses,
NALP3 inflammasome (alum)-induced IL-1b production signifi-
cantly declined with increasing age (when TLR co-stimulation was
provided) (Table 2 and Figure 1).
Alum Responses
We further examined alum-induced immune responses. Firstly,
alum-induced IL-1b responses were compared between CBMC
and PBMC of unrelated adult PNG donors and found to be
significantly higher in CBMC (Figure 3). Together with the
observation of decreasing alum-induced IL-1b levels during the
first 18 months of life, these findings imply that in this population
the alum response is likely highest at birth and progressively
declines throughout infancy and childhood. Secondly, the pro-
duction of additional alum-induced chemokines was assessed:
CXCL8 (IL-8) and MCP-1 (MCAF) also tended to decline with
increasing age in infancy, including a significant decline in
CXCL8 during the first 12 months of life (Figure 4). There were
no detectable age-related changes in any other alum-induced
chemokines measured including IP-10, MIP-1a (CCL3), MIP-1b
(CCL4) and eotaxin (CCL11) (Figure 4).
Discussion
In this study we have described postnatal innate immune
responses in relation to age in infants born in Papua New Guinea.
To our knowledge, this is the first study to address age-related
responses to NLR and inflammasome activation during infancy in
any population.
The most important finding was an age-related decline in
inflammatory responses to alum including IL-1b and CXCL8 (IL-
8), in particular during the first 12 months of life. This observation
could be of relevance for vaccine design and the implementation of
immunization schedules. Alum in the form of aluminum
hydroxide, aluminum phosphate, aluminum hydroxyphosphate
sulfate, or the here-studied aluminum potassium sulfate, is used as
an adjuvant in many pediatric vaccine formulations aiming to
enhance immune responses to vaccine antigens [33,34]. Following
vaccination, the alum-induced activation of the NALP3 inflam-
masome results in the induction of Th2-associated inflammation
and B cell isotype switching [25,35]. Moreover, alum induces
chemokines such as CXCL8 that recruit inflammatory cells to the
Table 3. Innate IL-10 responses in relation to increasing age in infancy.
IL-10 (pg/mL) 1–3 months 4–6 months 7–12 months 13–18 months Rho (slope)
TLR2 468 (148–1476) 1168 (686–1990) 1129 (735–1736) 1222 (862–1734) 0.124
TLR3 1554 (869–2779) 2014 (1041–3897) 1856 (812–4240) 3110 (2256–4288)* 0.230
TLR4 581 (208–1624) 691 (327–1461) 587 (386–894) 738 (394–1384) 20.092
TLR7/8 553 (158–1934) 755 (306–1863) 1146 (810–1622) 1530 (861–2716) 0.032
NOD1 2 (1–3) 2 (1–3) 4 (2–9) 2 (1–5) 0.279{
NOD2 9 (4–23) 13 (6–30) 10 (4–23) 10 (2–44) 20.008
NALP3 2 (1–3) 2 (1–2) 2 (1–2) 2 (2–2) 20.085
NALP3 ¤ 36 (9–136) 23 (5–97) 49 (16–151) 35 (5–260) 0.011
Presented are the geometric means and 95% confidence intervals (pg/mL) for background-adjusted IL-10 responses. Mann-Whitney U tests for significant differences in
log-transformed IL-10 levels compared to the ‘‘1–3 months’’ age group; and Spearman rho tests for significant correlations between log-transformed IL-10 levels and
ordered age groups were conducted. Significance level is indicated where p,0.05 only (* p= 0.046; { p=0.022).
¤denotes LPS co-stimulation used.
doi:10.1371/journal.pone.0036793.t003
Table 4. Innate TNF-a responses in relation to increasing age in infancy.
TNF-a (pg/mL) 1–3 months 4–6 months 7–12 months 13–18 months Rho (slope)
TLR2 102 (33–317) 135 (62–294) 81 (34–193) 104 (31–346) 20.081
TLR3 447 (181–1107) 540 (213–1370) 494 (227–1075) 476 (127–1782) 20.008
TLR4 224 (106–473) 100 (34–294) 59 (23–147)* 115 (41–321) 20.207
TLR7/8 182 (76–437) 110 (42–288) 99 (39–249) 47 (9–260) 20.178
NOD1 2 (1–2) 2 (2–4) 3 (2–4) 3 (2–5) 0.148
NOD2 3 (2–7) 8 (4–17) 5 (2–10) 8 (2–25) 0.140
NALP3 3 (2–5) 2 (1–3) 3 (2–4) 2 (1–5) 0.012
NALP3 ¤ 17 (4–76) 11 (3–39) 11 (4–32) 8 (2–34) 20.054
Presented are the geometric means and 95% confidence intervals (pg/mL) for background-adjusted TNF-a responses. Mann-Whitney U tests for significant differences in
log-transformed TNF-a levels compared to the ‘‘1–3 months’’ age group; and Spearman rho tests for significant correlations between log-transformed TNF-a levels and
ordered age groups were conducted. Significance level is indicated where p,0.05 only (* p= 0.049).
¤denotes LPS co-stimulation used.
doi:10.1371/journal.pone.0036793.t004
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site of vaccination and likely further boost vaccine responsiveness
[25,36]. Our finding that the immuno-stimulatory effects of alum
change with increasing age in infancy could therefore potentially
point at differences in the quality and/or quantity of the protective
immune response generated by alum-containing vaccines at
various stages of life. While the reason(s) for these age-related
differences are unclear to us, one possibility is that tolerance to
alum may occur following repeated exposure to alum-containing
vaccines at birth and throughout infancy. Interestingly, in mice,
effector and memory CD4+ T cells have been shown to selectively
block NALP3 inflammasome activation in an antigen-specific
manner to prevent potentially harmful inflammation [37]. It has
been speculated that such CD4+ memory cells generated during
primary immunisation dampen the NALP3-associated effects of
alum upon subsequent exposure to booster vaccinations [38].
While this has not yet been demonstrated in humans, it may be
a mechanism by which alum-induced inflammatory responses
progressively decline during infancy. Further investigations are
needed to determine whether these age-dependent changes in the
inflammatory response to alum alter vaccine efficacy and whether
this response pattern is unique to PNG infants or can be replicated
in other human infant populations.
A second finding of this study was that innate IL-10 responses
either increased or remained stable with age in the PNG study
infants: for example, IL-10 responses to TLR3 increased with age,
whilst responses to other studied TLR and NLR ligands remained
constant. This is in contrast to observations for children living in
high-income settings for whom TLR-mediated IL-10 responses
have been reported to decline between birth and 2 years of age
[12]; however, is in accord with findings for Gambian infants for
whom IL-10 responses to TLR ligands were reported to remain
stable to 12 months of age [10]. In line with the hygiene
hypothesis, this may suggest population differences in anti-
inflammatory responses throughout infancy. Speculatively, the
persistence of high IL-10 responses might protect against the
development of tissue damaging inflammation following frequent
immune challenge; but on the other hand, it may also contribute
to increased susceptibility to infections and may alter vaccine
responses in these populations [27].
Thirdly, in line with other studies including those performed in
high-income settings, pro-inflammatory responses to TLR activa-
tion, particularly to TLR2 and TLR3 agonists, increased with age
in our PNG infant study population. This included increased IL-6,
IL-1b and IFN-c, as well as increased TLR3-induced IL-12
production. These findings suggest that TLR2 and TLR3
pathways are subject to universal intrinsic ‘immune maturation’.
No clear changes in TNF-a production levels were observed across
age groups in our study, except for an age-related decrease in
response to TLR4 activation. Findings on TNF-a responses
throughout infancy are conflicting: studies from Europe, North
America and Australia have reported increasing LPS-induced
TNF-a levels over the first year of life [11–13], whereas in
Gambian infants, LPS-induced TNF-a responses remained stable
between 1 and 12 months of age [10]. Thus, there may be
population differences in age-related patterns of TNF-a production
during infancy; which we speculate is potentially a result of
differing environmental conditions. In line with the observed
increasing innate IL-10 responses, down-regulation of TNF-
a during infancy may further protect against harmful inflamma-
tory responses under the high microbial burden of the PNG
setting. On an additional note, TLR7/8-induced TNF-a pro-
duction was not particularly high in our study population, in
contrast to what has been reported during early life in other
populations [10,39]; at this stage it is unclear whether agonist
choice (gardiquimod versus R-848, imidazoquinoline congener
Figure 2. Maturation of innate IL-12 producing capacity during infancy. Whole blood samples from PNG infants aged 1–3 months (n = 18,
white bars), 4–6 months (n = 18, light grey bars), 7–12 months (n = 21, dark grey bars) or 13–18 months (n = 10, black bars) were stimulated with (A)
polyIC or (B) LPS with IFN-c priming. Presented are the geometric means and 95% confidence intervals (pg/mL) for each age group for background-
adjusted IL-12 responses. Significance level is indicated where p,0.10.
doi:10.1371/journal.pone.0036793.g002
Figure 3. Comparison of PNG cord and adult alum-induced IL-
1b production. Cord and peripheral blood mononuclear cells from
PNG newborns (n = 47) and PNG adults (n = 5), respectively were
stimulated with alum + LPS. Presented are the geometric means and
95% confidence intervals (pg/mL) for each age group for background-
adjusted IL-1b responses (i.e. LPS response was subtracted). Significance
level is indicated.
doi:10.1371/journal.pone.0036793.g003
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3 M-003 or thiazoloquinoline CLO75) and/or inherent popula-
tion differences explain these inconsistencies.
There is increasing evidence that the trajectory of early immune
developmentmayaffect theriskofdevelopingdiseases suchasallergy.
Tulic and colleagues recently demonstrated that inflammatory (IL-
1b, TNF-a, IL-6 and IL-12) responses toTLRactivationwere low at
birthbut increasedwithage innon-allergicAustralianchildren,while
the opposite trends were reported for allergic children [28]. In line
with findings for Australian non-allergic children, we found that
TLR-induced inflammatory (IL-1b, IL-6, IFN-c and IL-12)
responses in PNG children progressively increased during infancy.
Whilewehavenotdetermined theallergic statusof thechildren inour
study, another study performed in a comparable population in PNG
found no evidence of allergic sensitization in any of the individuals
tested [40]. Together with our other observations of quiescent
neonatal antigen presenting cell (APC) function in PNG newborns
and higher innate immune responsiveness in Australian newborns
(Lisciandro JG, manuscript in preparation), this suggests that
protection from allergic disease is characterized by low innate
immuneresponsiveness inearly life, followedbyprogressivepostnatal
maturation of inflammatory responses. Notably, prenatal environ-
mental exposures that influence the neonatal innate immune system
[41,42] likely play a significant role in determining the trajectory of
postnatal immune development and subsequent risk for allergic
disease.
There were a number of limitations to this exploratory study.
Firstly, the sample size was relatively small. Secondly, in accordance
withfindingsbyBlimkieandcolleagues[43],wewerenotable tomake
direct comparisons between cord and infant responses since cord
innate responses were earlier measured using in vitro CBMC
stimulations, while infant responses were measured in whole blood
cultures, owing to the low volume of venous blood obtainable from
infants. Despite these limitations, this study has demonstrated
important changes in the ontogeny of innate immune pathways
during infancy thatappear todiffer fromfindings fordevelopedworld
populations. Larger-sized confirmatory studies that include birth as
a time-pointwill provide further valuable insight into the ontogeny of
innate immune pathways in resource-poor settings.
Figure 4. Alum-induced chemokine production with increasing age in infancy. Whole blood samples from PNG infants aged 1–3 months
(n = 10, white bars), 4–6 months (n = 9, light grey bars), 7–12 months (n = 10, dark grey bars) or 13–18 months (n = 9, black bars) were stimulated with
Alum. Presented are the geometric means and 95% confidence intervals (pg/mL) for each age group for background-adjusted chemokine responses.
Significance level is indicated where p,0.10.
doi:10.1371/journal.pone.0036793.g004
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In conclusion, the ontogeny of innate immune responses may
vary between geographically diverse populations. Age-related
changes and geographical diversity in innate immune function
may explain differences between and within populations in
susceptibility to both infectious and non-communicable diseases,
and have important implications for vaccine design and imple-
mentation of vaccine schedules. Further studies particularly
addressing the ontogeny of responses to existing and candidate
vaccine adjuvants that are aimed at enhancing innate immune
function in early infancy require further attention.
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